Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Sylogent, a software and data services company, has announced the formal launch of PROJECTIC for the pharmaceutical industry. The web-based process management tool is designed to visualize milestones, projects and tasks across the enterprise with the push of a button. PROJECTIC is a flexible tool that allows for repetitive structured processes to be saved as templates that are managed by key data points. 

  • 5 August 2016
    Microbion’s MBN-101 receive Fast Track designation

    Microbion Corporation (“Microbion”) of Bozeman, MT, USA and Microbion Pharma Corp. of Vancouver, BC, Canada, specializing in the treatment of hard to treat and antibiotic-resistant infections, announced that the U.S. FDA has granted MBN-101 Fast Track designation for adjunctive treatment of mild and moderate diabetic foot ulcer infections.

  • GSK agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%. 

  • Allergan plc announced that it has completed the divestiture of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd. Allergan has received $33.4 billion in cash and 100.3 million shares of Teva stock valued at $5.4 billion based on the opening price of $53.39 for Teva Pharmaceutical Industries Ltd. shares on August 2, 2016. These shares are subject to a twelve month holding period post-close of the transaction.

  • Sorrento Therapeutics, Inc. an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced  that it has entered into a binding term sheet to create a joint venture  ("JV") with CHA Biotech Co. , LTD, of South Korea to develop and commercialize proprietary Chimeric Antigen Receptor ("CAR") modified cellular therapies based on CBT's Activated Killer Cell ("AKC") technology and five of  Sorrento's CARs for all disease conditions, including oncology and infectious diseases. The JV covers products on a global basis with the exception of the Greater Chinese market. 

  • Sun Pharma has announced that one of its subsidiaries has received final approval from US  FDA for its Abbreviated New Drug Application (ANDA) for generic version of Glumetza,  metformin hydrochloride extended release tablets 500 mg and 1000 mg. 

Subscribe to Pharma News